HitGen Inc. (SHA:688222)

China flag China · Delayed Price · Currency is CNY
27.61
+1.31 (4.98%)
At close: Jul 31, 2026
Market Cap11.06B +17.1%
Revenue (ttm)579.37M +35.9%
Net Income122.72M +86.8%
EPS0.30 +73.8%
Shares Out 400.68M
PE Ratio91.86
Forward PE81.21
Dividend0.13 (0.47%)
Ex-Dividend DateJun 18, 2026
Volume14,677,839
Open26.90
Previous Close26.30
Day's Range26.85 - 28.40
52-Week Range21.46 - 42.98
Beta0.52
Analystsn/a
Price Targetn/a
Earnings DateAug 27, 2026

About HitGen

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; virtual screening; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, which is in phase Ia clinical trial is a selective HDAC inhibitor for multipl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 546
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688222
Full Company Profile

Financial Performance

In 2025, HitGen's revenue was 525.57 million, an increase of 23.09% compared to the previous year's 426.99 million. Earnings were 109.51 million, an increase of 113.22%.

Financial Statements